IDEV develops and commercializes minimally invasive interventional devices, most notably the self‑expanding SUPERA® stent and the SUPERA VERITAS™ Peripheral Vascular System. The SUPERA stent is indicated in the US for palliative treatment of biliary strictures from malignant neoplasms and in Europe for biliary strictures and peripheral vascular use following failed PTA. The company recently launched the SUPERA VERITAS delivery system in Europe and operates there through an office in Beuningen, The Netherlands. IDEV completed a $46M Series D financing to support ongoing and planned clinical programs. Proceeds will fund a multi‑center IDE superficial femoral artery clinical trial for the SUPERA stent, additional peripheral artery clinical trials, development of new interventional products, and sales and marketing to support continued revenue growth.

Total raised

$46M

Funding rounds

1

Latest round

Series D

Latest activity

Oct 2010